Corporate Events

From July 1, 2026 to September 30, 2026, the company has repurchased 1,485,400 shares, representing 0.28% for ¥17,124.77 million. With this, the company has completed the repurchase of 4,283,500 shares, representing 0.81% for ¥47,035.76 million under the buyback announced on February 13, 2026.

Otsuka Holdings Co., Ltd. Presents at IASLC World Conference on Lung Cancer (WCLC) 2026, Sep-14-2026 08:00 AM. Venue: Seoul, South Korea. Speakers: Daniel Tan Shao Weng, Senior Consultant Medical Oncologist.

Otsuka Holdings Co., Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company revised revenue of JPY 2,725,000 million; Operating profit of JPY 469,000 million; Profit for the year of JPY 360,000 million; Profit attributable to owners of the Company of JPY 355,000 million; and Basic earnings per share of JPY 675.47 compared to previous guidance of revenue of JPY 2,520,000 million; Operating profit of JPY 360,000 million; Profit for the year of JPY 269,000 million; Profit attributable to owners of the Company of JPY 265,000 million; and Basic earnings per share of JPY 504.94. Based on the results for the first half of FY2026, the Company has revised upward the consolidated financial forecast announced on February 13, 2026. In the Pharmaceutical Business, the key growth drivers of the Fourth Medium-Term Management Plan, including the antipsychotic drug REXULTI, the antineoplastic agent LONSURF, and the anti-APRIL antibody VOYXACT, have continued to progress steadily. In addition, due to the later-than-anticipated entry of generic versions of JYNARQUE in the United States and ABILIFY MAINTENA in Europe, revenue in the Pharmaceutical Business is now expected to reach JPY 1,934.0 billion, exceeding the forecast announced in February 2026 by JPY 195.0 billion. In the Nutraceutical Business, the For Healthier Life category has continued to perform well, supporting solid business performance. The Company has also revised its foreign exchange assumptions to reflect the depreciation of the Japanese yen against the U.S. dollar and the euro (USD: JPY 150 to JPY 158; EUR: JPY 175 to JPY 185). As a result, revenue, business profit, operating profit, profit for the period, and profit attributable to owners of the Company are expected to exceed the previous forecast.

Otsuka Holdings Co., Ltd. announced the interim dividend of JPY 100.00 per share for the fiscal year ending December 31, 2026, payable on September 1, 2026 against JPY 70.00 per share a year ago. Record date: June 30, 2026. Total dividend amount JPY 52,539 million. Source of funds: Retained earnings. Provided dividend year end guidance for the fiscal year ending December 31, 2026. For the year end, the company expects dividend of JPY 100.00 per share against previous guidance of JPY 70.00 per share. Based on the favorable results for the second quarter of FY2026 and the upward revision of the consolidated financial forecast for the fiscal year ending December 31, 2026 announced today, the Company has revised the interim dividend from the previously forecast JPY 70.00 per share to JPY 100.00 per share. In line with its progressive dividend policy, the Company has revised the year-end dividend forecast from the previously forecast JPY 70.00 per share to JPY 100.00 per share, the same amount as the interim dividend. As a result, the Company plans to pay an annual dividend of JPY 200.00 per share (consisting of an interim dividend of JPY 100.00 and a year-end dividend of JPY 100.00), representing an increase of JPY 60.00 per share from the previous forecast.

Otsuka Holdings Co., Ltd., Board Meeting, Jul 31, 2026. Agenda: To consider and approve to revise the consolidated financial forecast for the fiscal year ending December 31, 2026; and to consider any other matters.

Otsuka Holdings Co., Ltd. revised consolidated earnings guidance for the first half ending June 30, 2026. For the period, the company now expects revenue of JPY 1,332,000 million, operating profit of JPY 278,000 million, profit for the period of the company of JPY 218,000 million, and basic earnings per share of JPY 407.90 compared to previous forecast for revenue of JPY 1,218,000 million, operating profit of JPY 175,000 million, profit for the period of JPY 131,000 million, and basic earnings per share of JPY 243.07. Reasons for the revision: Due to the favorable performance of its businesses during the interim consolidated accounting period, the Company has revised upward its consolidated earnings forecast announced on February 13, 2026. During the interim consolidated accounting period, revenue exceeded the previous forecast primarily due to the later-than- expected entry of generic versions of JYNARQUE in the United States and ABILIFY MAINTENA in Europe, strong performance of VOYXACT, REXULTI, and LONSURF, as well as the positive impact of foreign exchange rates, mainly reflecting the depreciation of the Japanese yen against the U.S. dollar and the euro. In addition, research and development expenses are expected to be lower than previously anticipated, mainly due to the discontinuation of development for certain indications of ulotaront and differences in the timing of expense recognition for development projects. As a result, revenue, business profit, operating profit, profit for the period, and profit attributable to owners of the Company are all expected to exceed the previous forecast.

From April 1, 2026 to June 30, 2026, the company has repurchased 1,985,400 shares, representing 0.38% for ¥21,475.77 million. With this, the company has completed the repurchase of 2,798,100 shares, representing 0.53% for ¥29,911 million under the buyback announced on February 13, 2026.

Otsuka Holdings Co., Ltd., Board Meeting, May 07, 2026. Agenda: To consider change in a Specified Subsidiary.

Otsuka Holdings Co., Ltd. announced that they will report Q2, 2026 results at 1:30 PM, Tokyo Standard Time on Jul 31, 2026

Otsuka Holdings Co., Ltd. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was JPY 630,342 million compared to JPY 582,840 million a year ago. Net income was JPY 98,348 million compared to JPY 84,997 million a year ago. Basic earnings per share from continuing operations was JPY 186.31 compared to JPY 158.57 a year ago.

Otsuka Holdings Co., Ltd., Q1 2026 Earnings Call, Apr 28, 2026

Information Meeting for the Acquisition of Transcend Therapeutics

International Association For The Study Of Lung Cancer, IASLC World Conference on Lung Cancer (WCLC) 2026, Sep 12, 2026 through Sep 15, 2026. Venue: Seoul, South Korea.

Otsuka Pharmaceutical Co., Ltd. announced that it has submitted a supplemental application in Japan seeking regulatory approval for an expanded indication of Iclusig (ponatinib hydrochloride) to include first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients. In conjunction with this application, Otsuka has also submitted a formulation addition for Iclusig 10 mg tablets, which will be required for use in first-line treatment. Iclusig is an oral tyrosine kinase inhibitor originally discovered by Ariad Pharmaceuticals Inc., which was acquired by Takeda in 2017. Otsuka holds the rights for the co-development and commercialization of Iclusig across nine Asian countries and regions, including Japan. The product was approved in Japan in 2016 for the treatment of chronic myeloid leukemia (CML) refractory or intolerant to prior therapies, and relapsed or refractory Ph+ ALL. Ph+ ALL is an aggressive form of leukemia characterized by the presence of the Philadelphia chromosome, which produces the BCR::ABL1 tyrosine kinase, a key driver of disease progression. Leukemic blasts--malignant immature lymphoid cells--proliferate primarily in the bone marrow, leading to rapid clinical deterioration. In the United States, Iclusig (U.S. product name: Iclusig) initially received approval for use as monotherapy in adult Ph+ ALL patients who are T315I-positive or for whom no other tyrosine kinase inhibitor (TKI) is indicated. In 2024, the U.S. FDA granted accelerated approval for Iclusig in combination with chemotherapy for first-line treatment of Ph+ ALL, further expanding its clinical utility. In Japan, treatment options for first-line management of Ph+ ALL remain limited, and there is a significant need for additional therapies to improve clinical outcomes. The newly submitted indication is therefore expected to provide an important new treatment option for patients with this high-risk leukemia. Iclusig is a tyrosine kinase inhibitor that targets the abnormal BCR::ABL1 tyrosine kinase expressed in CML and Ph+ ALL. It inhibits both wild-type BCR::ABL1 and clinically-relevant single mutations that confer resistance to other therapies, including the T315I mutation, and demonstrates efficacy in CML and Ph+ ALL. Iclusig received initial approvals in the United States in 2012 and in Europe in 2013. Otsuka obtained approval in Japan in 2016 and began marketing in the same year. The drug was designated as an orphan drug in Japan for CML resistant or intolerant to prior drug treatment and relapsed or refractory Ph+ ALL in 2015 and received additional orphan designation for Ph+ ALL in 2026. The first-line indication for adult patients with Ph+ ALL in combination with chemotherapy received accelerated approval in the U.S. in 2024, followed by approvals in several other countries, including those in Asia.

Otsuka Holdings Co., Ltd. expected to report First-Half, 2026 results on July 31, 2026. This event was calculated by S&P Global (Created on April 2, 2026).

From February 13, 2026 to March 31, 2026, the company has repurchased 812,700 shares, representing 0.15% for ¥8,435.22 million. With this, the company has completed the repurchase of 812,700 shares, representing 0.15% for ¥8,435.22 million under the buyback announced on February 13, 2026.

Otsuka Holdings Co., Ltd., Board Meeting, Mar 27, 2026. Agenda: To consider disposal of treasury shares as stock- based compensation (total amount to be paid in: estimated at ¥800 million) is planned for the next fiscal year.

Otsuka Holdings Co., Ltd. Presents at BIO Investment & Growth Summit, Mar-02-2026 . Venue: Eden Roc Miami Beach, Miami Beach, Florida, United States.

Annual Shareholders Meeting

Otsuka Holdings Co., Ltd. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was JPY 2,468,892 million compared to JPY 2,329,861 million a year ago. Net income was JPY 363,150 million compared to JPY 343,120 million a year ago. Basic earnings per share from continuing operations was JPY 685.06 compared to JPY 633.76 a year ago.

Otsuka Holdings Co., Ltd. announced that they will report Q1, 2026 results at 1:30 PM, Tokyo Standard Time on Apr 28, 2026

Otsuka Holdings Co., Ltd. expected to report Q1 2026 results on April 30, 2026. This event was calculated by S&P Global (Created on February 13, 2026).

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: ANA InterContinental Tokyo, B1F, Prominence 1-12-33 Akasaka, Minato-ku Tokyo Japan Agenda: To consider Business Report and Consolidated Financial Statements, as well as the audit reports of the Accounting Auditors and the Audit & Supervisory Board for Consolidated Financial Statements, for the 18th Fiscal Year (from January 1, 2025 to December 31, 2025); to consider Financial Statements for the 18th Fiscal Year (from January 1, 2025 to December 31, 2025); to consider Election of 13 Director & Board Members; and to consider Election of 4 Auditor & Supervisory Board Members.

Otsuka Holdings Co., Ltd. announced dividend of JPY 70.00 per share for the fiscal year ended December 31, 2025 as compared to JPY 60.00 per share a year ago. Scheduled date of dividend payment commencement: March 30, 2026.

Otsuka Holdings Co., Ltd. provided earnings guidance for the second quarter (year to date) and for the year ending December 31, 2026. For the second quarter (year to date), the company expected revenue of JPY 1,218,000 million; Operating profit of JPY 175,000 million; Profit of JPY 131,000 million; Profit attributable to owners of the Company of JPY 128,000 million; and Basic earnings per share of JPY 243.07. For the year, the company expected revenue of JPY 2,520,000 million; Operating profit of JPY 360,000 million; Profit for the year of JPY 269,000 million; Profit attributable to owners of the Company of JPY 265,000 million; and Basic earnings per share of JPY 504.94.

Otsuka Holdings Co., Ltd. provided dividend guidance for the second quarter and Year Ending December 31, 2026. For the quarter, the company expected dividend of JPY 70.00 per share as compared to JPY 70.00 per share a year ago. For the year, the company expected dividend of JPY 70.00 per share as compared to JPY 70.00 per share a year ago.

The Board of Directors of Otsuka Holdings Co., Ltd. has authorized a buyback plan on February 13, 2026.

Otsuka Holdings Co., Ltd. (TSE:4578) announces a share repurchase program. Under the program, the company will repurchase up to 7,000,000 shares, representing 1.33% of its share capital, for ¥50,000 million. The purpose of the program is to improve capital efficiency and return profits to shareholders. All the repurchased shares will be cancelled. The program will expire on December 23, 2026. As of December 31, 2025, the company had 528,131,369 shares in issue (excluding treasury stock) and 14,857,548 shares in treasury.

Biotechnology Innovation Organization, BIO Investment & Growth Summit, Mar 02, 2026 through Mar 03, 2026. Venue: Eden Roc Miami Beach, Miami Beach, Florida, United States.

Otsuka Pharmaceutical Co. Ltd. (Otsuka) announced that findings from a 12-month interim analysis of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults were presented in a late-breaking presentation session at the 2025 American Society of Nephrology (ASN) annual Kidney Week meeting in Houston, Texas. Summary data was simultaneously published in the online version of The New England Journal of Medicine. 12-month interim analysis outcomes for the novel APRIL antibody drug candidate sibeprenlimab, targeting IgA nephropathy, as part of the Phase 3 VISIONARY trial. Study outcome on proteinuria measured at 12 months demonstrated that sibeprenlimab achieved a 54.3% (95% confidence interval [CI, 46.4% to 60.9%) placebo-adjusted reduction. Trial outcomes presented at a late-breaking presentation session of the American Society of Nephrology (asN) Kidney Week, November 6 to 9, 2025. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure. Otsuka filed a Biologics License Application (BLA) for sibeprenlimab with the U.S. FDA and received a Priority Review designation from the agency, with a target action date (PDUFA date) of November 28, 2025. Twelve-month data on proteinuria levels, measured as urine-protein-to-creatinine ratio in 24-hour urine collections (uPCR-24), as well as on safety, from the Phase 3 VISIONARY study (NCT05248646) of Sibeprenlimab were submitted as part of the BLA (Biologics License Application) submission to the U.S. FDA. The VISIONARY study, the largest Phase 3 IgAN trial conducted to date, also showed that patients taking sibeprenlimab experienced substantially reduced serum immunoglobulins (IgA, IgG, IgM), A PRol proliferation-Inducing Ligand (APRIL), galactose-deficient IgA1 (Gd-IgA1) and rates of hematuria, and delivered higher proteinuric remission versus placebo, which is consistent with APRIL inhibition. Consistent treatment effects with Sibeprenlimab at nine-month effects were seen across prespecified subgroups, including those patients prescribed or not prescribed SGLT2 inhibitors, varying baseline proteinuria and estimated glomerular filtration rate (eGFR), demographics, and prior immunosuppression. Sibeprenlimab works by blocking APRIL, which plays a key role in the process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic galactose-deficiency IgA1 (Gd -IgA1). In inhibition of APRIL results in reduced levels of galactose-deficient IgA1 (Gd- IgA1), which is implicated in the pathogenesis of IgAN.2 Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration. Otsuka filed a biologics License Application (BL a Biologics License Application ("BLA") for sibepren Limab with the U.S., and the U.S. FDA, and received a priority Review designation from the agencies, with a target action date ("PDUFA date") of November 28, 2025. 12-month data on proteinuria level, measured as urine-protein -to-creatinine ratios in 24-hour urine collections ("uPCR-24"), as well as on safety.

Otsuka Holdings Co., Ltd. announced that they will report fiscal year 2025 results at 1:30 PM, Tokyo Standard Time on Feb 13, 2026

Otsuka Holdings Co., Ltd. provided consolidated financial forecast for the Fiscal Year Ending December 31, 2025. For the year, the company expects revenue of ¥2,420,000 million, operating profit of ¥452,000 million, Profit for the year of ¥334,000 million and Basic earnings per share of ¥622.52.

Otsuka Holdings Co., Ltd. expected to report Fiscal Year 2025 results on February 13, 2026. This event was calculated by S&P Global (Created on October 31, 2025).

Otsuka Holdings Co., Ltd., Q3 2025 Earnings Call, Oct 31, 2025